|
RIOK2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.71110000005237E-06 |
| Normal-vs-Stage3 |
4.16333634234434E-14 |
| Normal-vs-Stage4 |
2.62012633811537E-14 |
| Stage1-vs-Stage2 |
9.563900E-02 |
| Stage1-vs-Stage3 |
1.479190E-01 |
| Stage1-vs-Stage4 |
1.298080E-02 |
| Stage2-vs-Stage3 |
2.227800E-02 |
| Stage2-vs-Stage4 |
3.395300E-03 |
| Stage3-vs-Stage4 |
3.537400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
6.03339999999397E-05 |
| Normal-vs-Asian |
3.55950047215003E-10 |
| Caucasian-vs-AfricanAmerican |
2.294800E-01 |
| Caucasian-vs-Asian |
5.363000E-01 |
| AfricanAmerican-vs-Asian |
4.394200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.0547118733939E-13 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
8.001400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62803104331033E-12 |
| Normal-vs-Age(41-60Yrs) |
5.99520433297585E-15 |
| Normal-vs-Age(61-80Yrs) |
2.76245692987231E-12 |
| Normal-vs-Age(81-100Yrs) |
1.864280E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.642800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.548200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.076600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.574000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.415000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.243000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.018400E-03 |
| Classical-VS-Follicular |
9.725000E-01 |
| Classical-VS-Other |
5.270600E-01 |
| Classical-VS-Normal |
1.62470037423645E-12 |
| Tall-VS-Follicular |
6.076200E-03 |
| Tall-VS-Other |
4.184400E-01 |
| Tall-VS-Normal |
3.8924419243358E-13 |
| Follicular-VS-Other |
5.683200E-01 |
| Follicular-VS-Normal |
4.09070000095824E-10 |
| Other-VS-Normal |
1.223020E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.2854608750531E-14 |
| Normal-vs-N1 |
6.0285110237146E-13 |
| N0-vs-N1 |
4.214200E-02 |
|
|
